Evidence map›Paper›PMID 25501797›Full record

ArticleWorld journal of urology2015

Prostate histoscanning true targeting guided prostate biopsy: initial clinical experience.

Arjun Sivaraman, Rafael Sanchez-Salas, Eric Barret, Petr Macek, Pierre Validire, Marc Galiano, Francois Rozet, Xavier Cathelineau

Abstract read
PubMed Publisher
In one paragraph

Article in World journal of urology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
2.7field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Review
  6. HistoScanningCurrent urology reports · 2017
    Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Arjun SivaramanDepartment of Urology, Institute Mutualiste Monsouris, 42, Bd Jourdan, 75674, Paris Cedex 14, France.
Rafael Sanchez-SalasDepartment of Urology, Institute Mutualiste Monsouris, 42, Bd Jourdan, 75674, Paris Cedex 14, France. raersas@gmail.com.
Eric BarretDepartment of Urology, Institute Mutualiste Monsouris, 42, Bd Jourdan, 75674, Paris Cedex 14, France.
Petr MacekDepartment of Urology, Institute Mutualiste Monsouris, 42, Bd Jourdan, 75674, Paris Cedex 14, France.
Pierre ValidireDepartment of Pathology, Institute Mutualiste Monsouris, Paris, France.
Marc GalianoDepartment of Urology, Institute Mutualiste Monsouris, 42, Bd Jourdan, 75674, Paris Cedex 14, France.
Francois RozetDepartment of Urology, Institute Mutualiste Monsouris, 42, Bd Jourdan, 75674, Paris Cedex 14, France.
Xavier CathelineauDepartment of Urology, Institute Mutualiste Monsouris, 42, Bd Jourdan, 75674, Paris Cedex 14, France.
Institute Mutualiste Montsouris · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo evaluate the feasibility of prostate histoscanning true targeting (PHS-TT) guided transrectal ultrasound (TRUS) biopsy.

methodsThis is a prospective, single center, pilot study performed during February 2013-September 2013. All consecutive patients planned for prostate biopsy were included in the study, and all the procedure was performed by a single surgeon aided by the specialized true targeting software. Initially, the patients underwent PHS to map the abnormal areas within the prostate that were ≥0.2 cm(3). TRUS guided biopsies were performed targeting the abnormal areas with a specialized software. Additionally, routine bisextant biopsies were also taken. The final histopathology of the target cores was compared with the bisextant cores.

resultsA total of 43 patients underwent combined 'targeted PHS guided' and 'standard 12 core systematic' biopsies. The mean volume of abnormal area detected by PHS is 4.3 cm(3). The overall cancer detection rate was 46.5 % (20/43) with systemic cores and target cores detecting cancer in 44 % (19/43) and 26 % (11/43), respectively. The mean % cancer/core length of the PHS-TT cores were significantly higher than the systematic cores (55.4 vs. 37.5 %. p < 0.05). In biopsy naïve patients, the cancer detection rate (43.7 % vs. 14.8 %. p = 0.06) and the cancer positivity of the cores (30.1 vs. 6.8 %. p < 0.01) of target cores were higher than those patients with prior biopsies.

conclusionPHS-TT is feasible and can be an effective tool for real-time guidance of prostate biopsies.

Indexed as

EndosonographyFeasibility StudiesHumansImage-Guided BiopsyImaging, Three-DimensionalMaleMiddle AgedNeoplasm StagingPilot ProjectsProspective StudiesProstateProstatic NeoplasmsRectumReproducibility of ResultsProstate biopsyProstate cancerProstate histoscanningTarget biopsyTRUS biopsy

Identifiers

PMID25501797
OpenAlexW1971724718

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.